New Jersey Trim Clinic

You Can Afford This Medicine: GLP-1 Weight Loss in New Jersey for $5 a Day

Published by New Jersey Trim Clinic · Updated 2025-11-12

The Affordability Myth

If you have looked into GLP-1 weight loss medications — Ozempic, Wegovy, Mounjaro, Zepbound — you have probably been quoted $1,000 to $1,500 per month. That number alone has stopped thousands of New Jersey patients from ever starting treatment.

Here is the truth: you can afford this medicine. Not the $1,500 brand-name version. The same active molecules — semaglutide and tirzepatide — sourced through FDA-registered American compounding pharmacies, at a fraction of the cost.

👉 Check If You Qualify in 2 Minutes

$149 a Month — That's $5 a Day

New Jersey Trim Clinic offers GLP-1 therapy at $149 per month, all-inclusive. That includes:

  • The medication (semaglutide or tirzepatide)
  • Physician evaluation and ongoing supervision
  • Telehealth visits and follow-ups
  • Shipping to your door anywhere in NJ, NY, CT, PA
  • No membership fees
  • No surprise charges
  • No price gimmicks

Break that down and you are looking at about $5 a day — less than a Starbucks latte at the Bergen County mall, less than a Wawa breakfast sandwich on your way to work.

Why It's So Much Cheaper

The $1,500 brand-name price tag is not what the medication actually costs to produce. It reflects marketing budgets, brand premiums, insurance negotiation games, and middleman markups.

Compounded semaglutide and tirzepatide contain the same active pharmaceutical ingredients, are prepared by FDA-registered American pharmacies, and are prescribed under physician supervision. The savings come from cutting out the marketing premium — not from cutting corners on safety.

👉 Email info@newjerseytrimclinic.com — Get the Real Numbers

What About Insurance?

Most insurance plans in New Jersey do not cover GLP-1 medications for weight loss — even when they are medically appropriate. The bureaucratic process to fight for coverage can take months and often ends in denial.

Patients are tired of waiting. The $149/month all-inclusive cash-pay option lets you bypass insurance entirely and start treatment this week.

What Most NJ Patients Spend Without Realizing It

If you are wondering whether $149/month fits your budget, look at where money already goes:

  • DoorDash twice a week: $200+/month
  • Daily coffee shop runs: $150+/month
  • Late-night Uber Eats: $200+/month
  • Weekend takeout: $150+/month

Most NJ patients are already spending more than $149/month on the foods that fueled the weight gain. Redirecting a fraction of that toward physician-supervised treatment is not just affordable — it is one of the highest-ROI health decisions you can make.

👉 Start Losing Weight This Week — $149/mo all-inclusive

Plus the Promotional pricing: $189 New Jersey NAD+ Special

Looking for anti-aging and energy support too? Ask about our Promotional pricing: $189 New Jersey NAD+ special when you call. It pairs naturally with GLP-1 therapy and is one of the most popular add-ons for our NJ patients.

👉 Call (239) 422-6350 or email info@newjerseytrimclinic.com

Stop Letting Price Be the Reason

The medicine is here. The price is real. The physicians are board-certified. The pharmacies are FDA-registered. The only thing left is your decision.

👉 Get Approved Today

MEDICAL SOURCES & FURTHER READING

Read the source alongside the specific topic it supports. These independent sources do not endorse New Jersey Trim Clinic. Research findings are not a prediction of your results.

  • NIH/NIDDK — Prescription Medications to Treat Overweight & Obesity

    Supports: Weight-management medication requires individualized prescribing; eligibility, benefits, risks and ongoing treatment should be discussed with a healthcare professional. Nutrition and physical activity remain part of treatment.

  • Mayo Clinic — Prescription weight-loss drugs

    Supports: Prescription weight-loss medicines have eligibility restrictions, potential side effects and a need for professional oversight; they are used alongside lifestyle measures.

  • Cleveland Clinic — GLP-1 Agonists

    Supports: GLP-1 receptor agonists act on appetite and satiety, help regulate blood glucose and can slow stomach emptying. Common adverse effects include nausea, vomiting and diarrhea.

    Evidence limits: The extent and duration of effects differ by drug, dose and individual; a general mechanism does not establish a guaranteed response.

  • Once-Weekly Semaglutide in Adults with Overweight or Obesity

    Supports: Semaglutide 2.4 mg plus lifestyle intervention produced weight loss in the STEP 1 randomized trial; gastrointestinal adverse events were reported.

    Evidence limits: The main trial reported mean weight change of −14.9% at 68 weeks. This is not a predicted clinic outcome or proof that every semaglutide formulation has the same results.

  • FDA — Wegovy (semaglutide) prescribing information

    Supports: The approved product's label describes contraindications including personal or family history of medullary thyroid carcinoma and MEN 2, dose escalation, pregnancy considerations, gastrointestinal reactions, and warnings including pancreatitis, gallbladder disease and kidney injury due to volume depletion.

    Evidence limits: This label is for Wegovy, not approval of New Jersey Trim Clinic or a compounded formulation. Individual prescribing decisions require a licensed provider.

  • Tirzepatide Once Weekly for the Treatment of Obesity

    Supports: The SURMOUNT-1 trial studied tirzepatide at different doses in adults with obesity or overweight without diabetes and reported weight reduction and gastrointestinal adverse events.

    Evidence limits: SURMOUNT-1 was placebo-controlled, not a head-to-head comparison with semaglutide. Results do not establish guaranteed outcomes or equivalence of compounded medicines.

  • FDA — Concerns with Unapproved GLP-1 Drugs Used for Weight Loss

    Supports: Compounded GLP-1 drugs are not FDA-approved. FDA describes dosing, quality, storage and other safety concerns, and advises that compounded drugs should only be used when a patient's medical needs cannot be met by an FDA-approved drug.

    Evidence limits: Pharmacy registration is not FDA approval of a compounded product. Clinical trials of approved drugs do not establish the safety or effectiveness of compounded formulations.

  • A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD

    Supports: This exploratory pilot measured NAD+ and related metabolites during and after an intravenous infusion.

    Evidence limits: It did not establish anti-aging, longevity, improved energy, cognition or clinical benefit, and did not study the clinic's injection regimen. A biological role for NAD+ does not prove a treatment benefit.

RESEARCH & REFERENCES

General education is not individualized medical advice. Prescription treatment requires evaluation by a licensed provider. Eligibility, medication and dosing depend on individual circumstances.

Compounded drugs are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness or quality before marketing. Compounded drugs should only be used when a patient's medical needs cannot be met by an FDA-approved drug. Published studies of approved medications do not establish equivalent safety or effectiveness of compounded products.

Browse more New Jersey Trim Clinic patient education.